Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.53 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.53 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16392215 | 0.90 | ABCG2 (0.61) | ABCG2ABCB1ABCC1TGFBR1PDE4B | |
| SCHEMBL16391901 | 0.86 | ABCG2 (0.69) | ABCG2ABCB1ABCC1TGFBR1MEN1 | |
| SCHEMBL16391858 | 0.85 | ABCG2 (0.53) | ABCG2ABCB1ABCC1TGFBR1IDH1 | |
| SCHEMBL16392197 | 0.85 | ABCG2 (0.53) | ABCG2ABCB1ABCC1TGFBR1MAP4K4 | |
| SCHEMBL16392001 | 0.85 | ABCG2 (0.53) | ABCG2ABCB1ABCC1TGFBR1MEN1 | |
| SCHEMBL29561701 | 0.83 | IDH1 (0.56) | TGFBR1PDE4BIDH1PDE4D | |
| SCHEMBL15095057 | 0.83 | IDH1 (0.56) | TGFBR1PDE4BIDH1PDE4D | |
| SCHEMBL16392008 | 0.82 | ABCG2 (0.70) | ABCG2ABCB1ABCC1MEN1KMT2A | |
| SCHEMBL8347939 | 0.81 | TGFBR1 (0.56) | ABCG2ABCB1ABCC1TGFBR1PDE4B | |
| SCHEMBL8345581 | 0.81 | TGFBR1 (0.51) | ABCG2ABCB1ABCC1TGFBR1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019480-B1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10376510-B2 | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | disclosed |
| WO-2015006591-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | IDH2, IDH3B, IDH3A | ABCG2 889/4885ABCB1 828/4885ABCC1 367/4885 |
| US-10376510-B2 | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer | IDH2, IDH3B, IDH3A | ABCG2 889/4885ABCB1 828/4885ABCC1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.